An international, randomised, open label trial comparing a rituximab based regimen and a standard cyclophosphamide/azathioprine based regimen in the treatment of active 'generalised' ANCA associated vasculitis.
Phase of Trial: Phase II/III
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RITUXVAS